HUA MEDICINE (SHANGHAI) LTD. · 华领医药-B

Hua Medicine is an investment holding company primarily engaged in the development and commercialization of oral drug for the treatment of Type 2 diabetes. The Company is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The Company mainly conducts its businesses in the domestic market. Employees 328 Sector Biotechnology & Medical Research